Adagene Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Adagene Inc
Access all reports
Adagene Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company utilizes its proprietary technology platforms, including its Dynamic Precision Library (DPL) and SAFEbody technology, to engineer therapeutic antibodies with unique functional epitopes. These technologies enable the development of innovative monoclonal antibodies that target various cancers, aiming to improve both safety and efficacy. Adagene's product pipeline includes several candidates in various stages of clinical and preclinical development. The company is actively engaged in both mono and combination therapies, exploring new approaches to treat solid tumors and other cancer types.The company is headquartered in Suzhou, China, and its shares are listed on the NASDAQ.
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
ADAG
Country
🇺🇸 United States